Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADXS-NEO +/- pembrolizumab in advanced solid tumors
NCT03265080Phase 1Terminated
- Sponsor
- Advaxis, Inc.
- Start
- Mar 2018
- Primary completion
- Oct 2019
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of adxs-neo in colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 2 more (3 arms), sponsored by Advaxis, Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 20 months and Maximum Tolerated Dose at 4 weeks. Started Mar 2018; status: terminated.
02
Drugs
adxs-neo
03
Conditions
colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)melanoma
Beyond the preview
Go deeper on NCT03265080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03265080.